{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:49:38Z","timestamp":1776145778739,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.apjo.2026.100299","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:07:04Z","timestamp":1772557624000},"page":"100299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response \u2013 6-month interim analysis of the FURGGHORN study"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-084X","authenticated-orcid":false,"given":"Long T.","family":"Phan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey K.","family":"Broadhead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-9004","authenticated-orcid":false,"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5646-9359","authenticated-orcid":false,"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-2412","authenticated-orcid":false,"given":"Christopher Ziyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Luckie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeewa S.","family":"Wickremasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8713-7733","authenticated-orcid":false,"given":"Jagjit S.","family":"Gilhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-1356","authenticated-orcid":false,"given":"Matthew P.","family":"Simunovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-1585","authenticated-orcid":false,"given":"Andrew A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.apjo.2026.100299_bib1","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.2147\/OPTH.S185052","article-title":"The burden of neovascular age-related macular degeneration: a patient\u2019s perspective","author":"Spooner","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100299_bib2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.apjo.2026.100299_bib3","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100299_bib4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41433-021-01562-6","article-title":"Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series","volume":"36","author":"Garweg","year":"2022","journal-title":"Eye"},{"issue":"8","key":"10.1016\/j.apjo.2026.100299_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/aos.12463","article-title":"Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration","volume":"92","author":"Broadhead","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"issue":"10326","key":"10.1016\/j.apjo.2026.100299_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apjo.2026.100299_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S125676","article-title":"Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis","author":"Spooner","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100299_bib10","first-page":"1","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20136 month results","author":"Khanani","year":"2023","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100299_bib12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100299_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of Faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"6","key":"10.1016\/j.apjo.2026.100299_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to Faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100299_bib15","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of Faricimab treatment for AFLIBERCEPT-resistant neovascular age-related macular degeneration","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration","volume":"13","author":"Tamiya","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib17","volume":"10","author":"Phan","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10792-024-03297-1","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration","volume":"44","author":"Aldhanhani","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"18","key":"10.1016\/j.apjo.2026.100299_bib20","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.apjo.2026.100299_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab","volume":"9","author":"Sim","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"2","key":"10.1016\/j.apjo.2026.100299_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/jcm14020423","article-title":"Clinical Outcomes Following a Switch of Therapy to Faricimab in Patients Affected by Neovascular Age-Related Macular Degeneration","volume":"14","author":"Wolfrum","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.apjo.2026.100299_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2024","journal-title":"Front Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100299_bib24","article-title":"Comparison of 1-year outcomes after switching to faricimab in neovascular age-related macular degeneration previously treated with anti-VEGF agents with\/without a loading phase","author":"Hikichi","year":"2025","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100299_bib25","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00417-013-2332-5","article-title":"Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark","volume":"251","author":"Tschuor","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100299_bib26","series-title":"Immunogenicity: clouding the future of intravitreal therapy","first-page":"1746","author":"Sharma","year":"2023"},{"issue":"8","key":"10.1016\/j.apjo.2026.100299_bib27","article-title":"Effectiveness and safety of faricimab in eyes with nAMD in the United Kingdom: 18-month results from the FARWIDE-nAMD study","volume":"66","author":"Varma","year":"2025","journal-title":"Invest Ophthalmol & Vis Sci"},{"issue":"8","key":"10.1016\/j.apjo.2026.100299_bib28","article-title":"Two-year real-world clinical outcomes in patients with neovascular age-related macular degeneration treated with faricimab in the US: The FARETINA-nAMD study","volume":"66","author":"Borkar","year":"2025","journal-title":"Invest Ophthalmol & Vis Sci"},{"issue":"8","key":"10.1016\/j.apjo.2026.100299_bib29","article-title":"Global real-world clinical and anatomical outcomes with faricimab in treatment-na\u00efve patients with nAMD or DME from a prospective non-interventional study: The VOYAGER study","volume":"66","author":"Guymer","year":"2025","journal-title":"Invest Ophthalmol & Vis Sci"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:03:49Z","timestamp":1776143029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162098926000253"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100299","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faricimab for previously-treated eyes with neovascular age-related macular degeneration with inadequate response \u2013 6-month interim analysis of the FURGGHORN study","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100299"}}